

**UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION**

COMMISSIONERS: **Joseph J. Simons, Chairman**
 Noah Joshua Phillips
 Rohit Chopra
 Rebecca Kelly Slaughter
 Christine S. Wilson

In the Matter of)	
)	
PFIZER INC.,)	
a corporation;)	
)	
UPJOHN INC.,)	
a corporation;)	
)	Docket No. C-4727
VIATRIS INC.,)	
a corporation;)	
)	
MYLAN N.V.,)	
a corporation;)	
)	
and)	
)	
UTAH ACQUISITION SUB INC.,)	
a corporation.)	

COMPLAINT

Pursuant to the Clayton Act and the Federal Trade Commission Act (“FTC Act”), and its authority thereunder, the Federal Trade Commission (“Commission”), having reason to believe that Respondent Pfizer Inc. proposes to combine certain of its assets and liabilities, including Respondent Upjohn Inc. and Respondent Utah Acquisition Sub Inc., with Respondent Mylan N.V. to form Respondent Viatrix Inc., all Respondents being corporations subject to the jurisdiction of the Commission, in violation of Section 5 of the FTC Act, as amended, 15 U.S.C. § 45, and that such combination, if consummated, would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the FTC Act, as amended, 15 U.S.C. § 45, and it appearing to the Commission that a proceeding in respect thereof would be in the public interest, hereby issues its Complaint, stating its charges as follows:

I. RESPONDENTS

1. Respondent Pfizer Inc. is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and principal place of business located at 235 East 42nd Street, New York, New York 10017.
2. Respondent Upjohn Inc. is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and principal place of business located at 235 East 42nd Street, New York, New York 10017. Upjohn houses Pfizer's authorized generic distributor, Greenstone LLC. After the proposed transaction, Upjohn Inc. is to be renamed Viatrix Inc.
3. Respondent Viatrix Inc. is or will be a successor corporation of Upjohn Inc. Viatrix is or will be a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and principal place of business located at 1000 Mylan Boulevard, Canonsburg, Pennsylvania 15317.
4. Respondent Mylan N.V. is a public limited liability company organized, existing, and doing business under and by virtue of the laws of the Kingdom of the Netherlands with its executive offices and principal place of business located at Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, England. Mylan N.V. includes Mylan I B.V. and Mylan II B.V. (collectively, "Respondent Mylan"). Mylan N.V.'s United States address for service of process is Mylan Inc., 1000 Mylan Boulevard, Canonsburg, Pennsylvania 15317.
5. Respondent Utah Acquisition Sub Inc. is a corporation organized, existing, and doing business under and by virtue of the laws of the State of Delaware with its executive offices and principal place of business located at 235 East 42nd Street, New York, New York 10017.
6. Each Respondent is, and at all times relevant herein has been or will be, engaged in commerce, as "commerce" is defined in Section 1 of the Clayton Act as amended, 15 U.S.C. § 12, and engages in business that is in or affects commerce, as "commerce" is defined in Section 4 of the FTC Act, as amended, 15 U.S.C. § 44.

II. THE PROPOSED COMBINATION

7. Pursuant to a Separation and Distribution Agreement by and between Pfizer Inc. and Upjohn Inc., dated July 29, 2019, and the Business Combination Agreement by and among Pfizer Inc., Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V., and Mylan II B.V., dated July 29, 2019 (collectively, the "Agreements"), Respondent

Pfizer will combine certain of its assets and liabilities with Respondent Mylan to form Respondent Viartis (the “Combination”). Respondent Pfizer will receive \$12 billion in cash from Viartis as partial consideration in connection with the Combination, and Respondent Pfizer’s shareholders will gain an interest in Respondent Viartis. The Combination is subject to Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18.

III. THE RELEVANT MARKETS

8. The relevant lines of commerce in which to analyze the effects of the Combination are the development, license, manufacture, marketing, distribution, and sale of the following generic pharmaceutical products:
 - a. Amlodipine besylate/atorvastatin calcium tablets;
 - b. Eplerenone tablets;
 - c. Gatifloxacin ophthalmic solution;
 - d. Levothyroxine sodium tablets;
 - e. Medroxyprogesterone acetate injectable solution;
 - f. Phenytoin chewable tablets;
 - g. Prazosin hydrochloride capsules;
 - h. Spironolactone hydrochlorothiazide tablets;
 - i. Sucralfate tablets; and
 - j. Varenicline tartrate tablets.
9. The United States is the relevant geographic area in which to assess the competitive effects of the Combination in the relevant lines of commerce.

IV. THE STRUCTURE OF THE MARKETS

10. Amlodipine besylate/atorvastatin calcium tablets combine a calcium channel blocker to treat hypertension with a lipid-lowering agent to treat high cholesterol. Only four companies sell generic amlodipine besylate/atorvastatin calcium tablets: Greenstone, Mylan, Dr. Reddy’s Laboratories Ltd., and Apotex Inc. The Combination will reduce the number of current suppliers from four to three. In all eleven strengths of amlodipine

besylate/atorvastatin calcium tablets, Greenstone and Mylan account for greater than 30 percent of the market combined.

11. Eplerenone is a diuretic that is prescribed as an adjunctive therapy when treating hypertension or congestive heart failure after a heart attack. Significant sellers of eplerenone include Greenstone, Mylan, Breckenridge Pharmaceutical, Inc., and Accord Healthcare Inc. In both the 25mg and 50mg strengths, the Combination would reduce the number of significant suppliers and result in the combined entity accounting for approximately 50 percent of eplerenone tablets sold.
12. Gatifloxacin ophthalmic solution is an eye drop that treats bacterial conjunctivitis caused by susceptible strains of certain bacteria. The market for gatifloxacin has faced historical supply disruptions. Five companies supply this product today: Greenstone, Mylan, Sandoz International GmbH, Akorn, Inc., and Lupin Ltd. Together, Greenstone and Mylan account for more than 60 percent of gatifloxacin sales.
13. Levothyroxine sodium tablets are offered in a host of strengths and are prescribed to treat hypothyroidism or as an adjunct therapy for patients undergoing treatment for thyroid cancer. Suppliers for levothyroxine sodium tablets vary by strength. Should Upjohn or Greenstone launch an authorized generic of Pfizer's levothyroxine sodium branded product (Levoxyl®), the Combination would likely allow the combined entity to reduce the number of independent suppliers of some strengths of generic levothyroxine sodium tablets from three to two.
14. Medroxyprogesterone acetate is an injectable solution used to treat certain types of dysfunctional uterine bleeding. Injectable products, such as medroxyprogesterone acetate, often experience shortages and supply disruptions. Greenstone, Mylan, Amphastar Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd. currently supply medroxyprogesterone acetate. Combined, Greenstone and Mylan account for more than 50 percent of the market.
15. Phenytoin chewable tablets are an anti-epileptic drug that slows down impulses in the brain that cause seizures. Only three suppliers provide phenytoin chewable tablets today: Greenstone, Mylan, and Taro Pharmaceutical Industries Ltd. The Combination would reduce the number of available suppliers and result in Greenstone and Mylan accounting for more than 40 percent of phenytoin chewable tablets sold.
16. Prazosin hydrochloride (HCl) capsules are an alpha-adrenergic blocker that treats hypertension by relaxing the veins and arteries so that blood can more easily pass. The market for prazosin HCl capsules is supplied by four companies: Greenstone, Mylan, Teva, and Novitium Pharma LLC. Across the three strengths of prazosin HCl available today, the Combination would reduce the number of available suppliers and result in the combined entity accounting for approximately half of prazosin HCl capsules sold.

17. Spironolactone hydrochlorothiazide (HCTZ) tablets are a diuretic used to treat hypertension. Only three suppliers provide spironolactone HCTZ tablets: Greenstone, Mylan, and Sun. The Combination would reduce the number of suppliers from three to two and result in Greenstone and Mylan accounting for more than 30 percent of the market.
18. Sucralfate tablets are used to treat and prevent ulcers in the small intestines. Prior to the proposed Combination, only three companies sold sucralfate tablets historically: Greenstone, Mylan, and Teva. While Mylan has stopped selling sucralfate recently, the proposed Combination likely alters Mylan's incentives to relaunch sucralfate tablets and would reduce the number of firms capable of selling sucralfate tablets from three to two.
19. Varenicline tartrate tablets are a smoking cessation aid offered under Pfizer's brand Chantix®. Currently, only branded Chantix® is available in the market. Mylan is one of a limited number of companies likely to share the Hatch-Waxman 180-day exclusivity period when the generic market forms. Should Upjohn or Greenstone launch an authorized generic of Pfizer's Chantix®, the Combination would likely allow the combined entity to reduce the small number of independent suppliers that would have sold generic varenicline tartrate tablets during the Hatch-Waxman exclusivity period absent the Combination.

V. ENTRY CONDITIONS

20. Entry into the relevant markets described in Paragraphs 10-19 would not be timely, likely, or sufficient in magnitude, character, and scope to deter or counteract the anticompetitive effects of the Combination. *De novo* entry would not take place in a timely manner because the combination of drug development times and FDA approval requirements would be lengthy. In addition, no other entry is likely to occur such that it would be timely and sufficient to deter or counteract the competitive harm likely to result from the Combination.

VI. EFFECTS OF THE COMBINATION

21. The effects of the Combination, if consummated, may be to substantially lessen competition in violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the FTC Act, as amended, 15 U.S.C. § 45, in the following ways, among others:
 - a. by eliminating actual, direct, and substantial competition between Upjohn and Greenstone and Mylan and reducing the number of independent significant competitors in the markets for: (1) generic amlodipine besylate/atorvastatin calcium tablets; (2) generic eplerenone tablets; (3) generic gatifloxacin ophthalmic

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.